Rhythm Pharmaceuticals, Inc. (RYTM) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Boston, MA, 美国. 現任CEO為 David Meeker.
RYTM 擁有 IPO日期為 2017-10-09, 283 名全職員工, 在 NASDAQ Global Market, 市值為 $5.96B.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of therapeutics for rare genetic diseases of obesity. The company's lead product, IMCIVREE, is a melanocortin-4 receptor agonist approved for treating obesity caused by POMC, PCSK1, and LEPR deficiencies, as well as Bardet-Biedl and Alström syndromes. Rhythm is also advancing setmelanotide through Phase II clinical trials for multiple rare genetic obesity indications, including heterozygous POMC or LEPR deficiency, SH2B1 deficiency, MC4 receptor deficiency, and Smith-Magenis syndrome. Founded in 2008 and formerly known as Rhythm Metabolic, Inc., the company collaborates with leading clinical research organizations to advance its pipeline and address significant unmet medical needs in rare genetic obesity.
